KLRS (Kalaris Therapeutics Inc) Stock Financials & Earnings

KLRSKalaris Therapeutics Inc

Mkt Cap$187M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$52M

EPS (TTM)-$7.41

Free Cash Flow (TTM)-$38M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

▶Q3 2025

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening vi...

CEO Andrew OxtobyIPO Jul 30, 2020kalaristx.com

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	-$1M	-$40M
Q1 23	$0	-$547K	-$43M
Q2 23	$0	$0	-$47M
Q3 23	$0	-$4M	-$47M
Q4 23	$0	$0	-$3M
Q1 24	$0	$0	-$3M
Q2 24	$0	$0	-$4M
Q3 24	$0	$0	-$38M
Q4 24	$0	$0	-$20M
Q1 25	$0	$0	-$10M
Q2 25	$0	$0	-$12M
Q3 25	$0	$0	-$13M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$35M	-$35M
Q4 22	-$32M	-$32M
Q1 23	-$32M	-$32M
Q2 23	-$27M	-$27M
Q3 23	-$34M	-$34M
Q4 23	-$4M	-$4M
Q1 24	-$5M	-$5M
Q2 24	-$4M	-$4M
Q3 24	-$4M	-$4M
Q1 25	-$7M	-$7M
Q2 25	-$15M	-$15M
Q3 25	-$11M	-$12M

Capital Expenditures

CapEx

Quarter	CapEx
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$183K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	-27.5%
Q1 23	—	+0.1%
Q2 23	—	+6.0%
Q3 23	—	+9.3%
Q4 23	—	-91.4%
Q1 24	—	-94.1%
Q2 24	—	-91.1%
Q3 24	—	-19.4%
Q4 24	—	+463.6%
Q1 25	—	+304.0%
Q2 25	—	+192.7%
Q3 25	—	-66.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$31K	—
Q1 24	$31K	—
Q2 24	$322K	—
Q3 24	$262K	—
Q1 25	$374K	—
Q2 25	$0	—
Q3 25	$638K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$27M	—	$12M
Q1 23	$30M	—	$13M
Q2 23	$35M	—	$12M
Q3 23	$31M	—	$13M
Q4 23	$3M	$498K	—
Q1 24	$2M	$602K	—
Q2 24	$3M	$976K	—
Q3 24	$36M	$2M	—
Q4 24	$320K	—	$19M
Q1 25	$6M	$4M	—
Q2 25	$8M	$4M	—
Q3 25	$9M	$4M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$106M	$128M	$234M
Q1 23	$116M	$87M	$203M
Q2 23	$197M	$50M	$247M
Q3 23	$96M	$118M	$213M
Q4 23	$3M	$0	$3M
Q1 24	$86M	$54M	$141M
Q2 24	$105M	$25M	$130M
Q3 24	$2M	$0	$2M
Q4 24	$118M	$0	$118M
Q1 25	$101M	$0	$101M
Q2 25	$88M	$0	$88M
Q3 25	$42M	$35M	$77M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	4M	+9.6%
Q1 23	4M	+0.2%
Q2 23	4M	+1.4%
Q3 23	5M	+20.4%
Q4 23	5M	+0.1%
Q1 24	5M	+0.5%
Q2 24	5M	+0.0%
Q3 24	5M	+0.0%
Q4 24	5M	+0.8%
Q1 25	4M	-19.3%
Q2 25	19M	+361.4%
Q3 25	19M	+0.0%